Company intelligence / Profile preview
Oragenics, Inc.
Tampa, Florida, United Statesoragenics.com ↗
- Ownership
- Public · OGEN
- Development stage
- Phase 2
01
Overview
Oragenics has completed synthesis of ONP-002 batch for a planned Phase II clinical trial, with testing demonstrating over 99% purity after three months of stability[5]. The company has made a Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial[6].
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- NeurosteroidsIntranasal drug delivery
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Financials
- Market cap
- $1.6M
- Total revenue
- $0
- Enterprise value
- $-2.3M
Beyond the preview
Go deeper on Oragenics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oragenics, Inc..